← Back to Clinical Trials
Recruiting Phase 4 NCT03781765

NCT03781765 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03781765
Status Recruiting
Phase Phase 4
Sponsor Icahn School of Medicine at Mount Sinai
Condition ADHD
Study Type INTERVENTIONAL
Enrollment 44 participants
Start Date 2019-06-04
Primary Completion 2025-09-25

Trial Parameters

Condition ADHD
Sponsor Icahn School of Medicine at Mount Sinai
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 44
Sex ALL
Min Age 7 Years
Max Age 12 Years
Start Date 2019-06-04
Completion 2025-09-25
Interventions
MethylphenidateAtomoxetine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The study team will examine the effects of FDA approved stimulant and non-stimulant medications for ADHD, among youth with ADHD and with and without Oppositional Defiant Disorder (ODD) or Conduct Disorder (CD), on reward systems of the brain using fMRI.

Eligibility Criteria

Inclusion Criteria: * Pre-pubertal (e.g. Tanner stage 1 or 2) * Age 7-12 inclusive * Signed consent/assent * Parent communicates sufficiently in English to provide informed consent and complete assessment instruments; * ADHD as determined by computerized DISC (C-DISC) parent interview * ADHD-Rating Scale-5 total score (interview with parent ) * SNAP ADHD total score (teacher) of 1.5 SD \> age/sex norms * CD or severe ODD: CD or ODD + 2 symptoms of CD on C-DISC * SNAP ODD/CD subscale (parent and teacher) 1.5 SD \> age/sex norms Exclusion Criteria: * Major neurological/medical illness * History of head injury * Fetal exposure to alcohol/drugs * Diagnosis of major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, generalized anxiety, social phobia, Tourette's Disorder, PTSD, autism spectrum disorder) * Current suicidal ideation or past history of suicide attempt * Wechsler Abbreviated Scale of Intelligence (WASI)75 score \<75 * Prior or current treatment with

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology